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The present paper reviews the evidence as to whether patients on lipid-lowering drugs should
restrict dietary SFA intake. Premature mortality from atherosclerotic CVD has fallen dra-
matically in many high-income countries. This appears to be due to a combination of
improved treatment following a cardiovascular event and reduced risk factors, including
LDL-cholesterol. Whether this reduction is due to changes in dietary habits, or the increas-
ing availability of highly potent cholesterol-reducing drugs remains to be firmly established.
While reducing dietary SFA intake has been the cornerstone of public health nutrition policy
for several decades, the efficacy of such dietary changes has been challenged in recent years.
While there remains a lack of consensus in the literature, there is an emerging view that diet-
ary advice should be specifically modified to emphasise replacing SFA with PUFA in the
diet rather than carbohydrate. The advice to moderate dietary SFA intake given to the gen-
eral population is usually also given to those individuals at high risk of CVD who are pre-
scribed lipid-lowering drugs. There is limited evidence to suggest that any potential benefit of
such a diet on LDL-cholesterol may be offset by a concurrent decrease in HDL-cholesterol.
However, as diets rich in SFA are frequently energy-dense, and rich in red and processed
meat (potential risk factors for CVD in themselves), it would seem prudent to continue to
advise patients on lipid-lowering drugs to maintain a low-fat diet.
Cholesterol: Drugs: Dietary fat: CVD
Atherosclerotic CVD, including stroke and CHD, are
major causes of morbidity and mortality across the
world. In 2015, it was estimated that there were 422·7 mil-
lion cases of CVD which resulted in 17·92 million deaths(1).
Between 1990 and 2015, there was a dramatic decline in
CVD in countries with very high socioeconomic indices,
but much lower reductions (or no change/increases) in
poorer countries(1) In the UK, between 2002 and 2010,
age-adjusted mortality from acute myocardial infarction
fell by approximately half(2). In men, 57 % of this reduction
was due to a drop in the number of events, while the other
43 % were due to improved case-mortality rates, with
equivalent figures for women of 52 and 48 %, respectively.
Over a similar period (1999–2008), the incidence of stroke
fell by approximately 30 %, and mortality in the first 56 d
following a stroke fell from 21 to 12 %(3). One of the
major reasons for decline in mortality is improvement
in post-event care and treatment. A major development
in the treatment of patients, post-myocardial infarction,
has been the use of percutaneous coronary interventions
(stents) to open and maintain the blood flow in the
affected artery. In the UK, between 1991 and 2013,
there was an almost 10-fold increase in such treatment,
rising from 9933 to 92 589 procedures(4).
The other major reason for the decline in CVD in
more affluent countries is changes in risk factors leading
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to a decrease in incidence. Tobacco smoking, hyperten-
sion and plasma cholesterol (raised LDL and/or
decreased HDL) represent the three major modifiable
risk factors for CVD. The most dramatic decline in
these risk factors has been in smoking. Between 1974
and 2017, in the UK, the number of adults over the
age of 16 years who smoked, dropped from 45·6 %
(males 51·4 %, females 40·7 %) to 16·8 % (males 18·7 %,
females 15·0 %)(5) with the biggest fall in adults over
the age of 50 years. While similar trends have been
seen in most high-income countries, it is not true for all
regions, with smoking in African and the Eastern
Mediterranean region rising rapidly(6). In the UK,
improvements have also been seen in the proportion of
adults with hypertension. The Health Survey for
England reports a modest fall in the number of adults
with hypertension from 31 % of the population in 2002
to 27 % in 2017(7). However, much more significant is
the decline in the proportion with uncontrolled or
untreated hypertension, from 25 to 16 %, over the same
period. However, it is important to note that uncon-
trolled/untreated hypertension continues to rise in many
developing parts of the world and represents a major
public health problem(8). Similar regional differences
have been seen in changes in plasma cholesterol.
Globally, there was little change in the mean plasma
cholesterol between 1980 and 2008(9). However, under-
lying this were declines in high-income regions, including
Australasia, North America and Western Europe, but
increases in other parts of the world such as East and
South East Asia and the Pacific. The relative impact of
dietary changes and drug therapy on plasma cholesterol
in more affluent countries remains to be fully established
and is discussed in the following sections.
Impact of dietary fatty acids on plasma cholesterol and
cardiovascular risk
A link between raised plasma cholesterol and the devel-
opment of atherosclerosis has been recognised for over
a century. In 1948, Morrison et al.(10) published one of
the first studies showing that individuals with premature
(age under 60 years) coronary thrombosis were more
likely to have elevated cholesterol. In the 1950s, the
development of techniques to separate lipoproteins led
to the discovery that it was cholesterol carried by LDL
that was specifically associated with atherosclerosis(11).
Subsequently the protective effects of HDL began to
emerge and were confirmed in two major prospective
studies: the Tromso Heart Study(12) and the
Framingham Population Study(13). Such findings inevit-
ably led to the question of what causes the variation in
lipoprotein concentrations within populations. While in
a small number of individuals this could be attributed
to specific genetic mutations, or polymorphisms, it was
clear that other factors must also be involved. While in
most animals species, feeding excess cholesterol is
required to initiate the development of atherosclerosis,
it became increasingly clear that the amount and type
of fat fed could also impact on the rate of
development(14). The now infamous Seven Countries
Studies, published by Keys et al.(15) was one of the first
to demonstrate a relationship between dietary SFA
intake, plasma cholesterol and cardiovascular risk in
human subjects. The design, presentation and interpret-
ation of the results of this study are still hotly debated.
However, it is perhaps the carefully controlled human
feeding studies performed by Keys et al.(16), and inde-
pendently by Hegsted et al.(17), that most clearly
demonstrated a clear quantitative relationship between
the amount and type of fatty acids consumed and the
level of plasma cholesterol. Both groups clearly showed
that SFA increased plasma cholesterol, while PUFA
reduced it. Furthermore, both agreed that the impact
of SFA was more potent than that of PUFA.
Subsequent studies have refined this relationship indi-
cating effects on both LDL- and HDL-cholesterol
and identifying that the chain length of the SFA plays
an important role, with lauric (C12:0), palmitic
(C14:0) and palmitic (C16:0) have the greatest impact
on LDL-cholesterol(18,19). Further work also highlighted
the potent effect of trans fatty acids (TFA), particularly
those associated with partially hydrogenated oils, on
LDL-cholesterol(18,19). Such findings have underpinned
the dietary recommendations for reduction of CVD
across the world. In the UK, the Committee on Medical
Aspects of Food Policy(20,21) set specific guidelines
such that the average contribution of total fat to dietary
energy in the population should be reduced to 35 % and
SFA and TFA should be reduced to 10 and 2 %, respect-
ively. However, they recommended that n-6 PUFA should
not increase further and no specific recommendations were
made for MUFA. These, and similar recommendations
around the world, have remained a cornerstone of public
health policy to reduce CVD for the past 30 years.
Recent years have seen considerable debate, in both the
scientific and popular press as to whether such dietary
policies were warranted, or whether they have had any
positive impact on CVD outcomes. The National Diet
and Nutrition Survey(22,23) showed that intake of SFA
and TFA, as a proportion of dietary energy, dropped
markedly, from 16 to 13·6 %, between 1986/87 and
2000/01. However, in recent years, there has been little
further change in SFA intake which, in the 2014/15–
2015/16 survey(24), was still standing at 11·9 % (although
TFA had fallen further to only 0·5 % of total energy
intake). When these data are compared with those for
plasma cholesterol, over a similar period there was a
steady drop in mean plasma cholesterol, in adults,
between 1985 and 2005 (from 6·2 to 5·4 mM), which has
remained stable in more recent years(25). While it is tempt-
ing to link the drop in SFA intake with that in cholesterol,
and indeed CVD mortality, this should be done with cau-
tion due to both the increasing use of cholesterol-lowering
drugs (mentioned later) and changes in other potential
risk factors already discussed.
While reducing SFA intake has remained a major goal
in many countries for the past 30 years, there has been
increasing debate over the actual relationship between
fat intake and cardiovascular mortality/morbidity. This
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of systematic reviews and meta-analyses of both cohort
and intervention studies, some of which are summarised
in Table 1. Some of these have challenged any link of
SFA with CVD morbidity/mortality(26–28) while others
have specifically emphasised the value of replacing SFA
with n-6 PUFA in the diet(29–33). Of the latter, perhaps
the most compelling is the Cochrane Review of Hooper
et al.(33) who, having reviewed fifteen randomly con-
trolled trials (including 59 000 participants) of various
strategies for reducing SFA intake, concluded that
replacing SFA with PUFA is a useful strategy to reduce
CVD risk, while replacing with carbohydrate appears to
be of little value. Due to the limited evidence available
relating to replacing SFA with MUFA, they felt unable
to reach a conclusion as to the potential benefit.
These overall conclusions are generally reflected in the
recently updated draft reports from both the World
Health Organisation(34) and the UK Scientific Advisory
Committee on Nutrition(35) which continue to support
reducing SFA intake but with more emphasis on replace-
ment with n-6 PUFA.
The National Institute for Health and Care Excellence
(NICE) provides specific advice about dietary fat intakes
for patients with elevated plasma cholesterol, who are at
increased risk of developing (or who already have) CVD.
Their recommendations suggest such patients should be
encouraged to reduce their intake of SFA to <7 % of
total energy intake(36).
Statins, plasma cholesterol and cardiovascular risk
Until the late 1980s, pharmaceutical interventions for
reducing plasma cholesterol were limited. The most widely
used treatment was administration of bile acid binding
agents, such as cholestyramine or colestipol, which act
by binding to bile acids in the intestine, increasing their
excretion and requiring the liver to synthesise more from
cholesterol(37). The resulting decrease in hepatic choles-
terol leads to an increase in LDL receptor expression,
thus increasing removal of LDL particles from the circu-
lation. However, the beneficial effects are partly offset
by an increase in cholesterol synthesis in the liver(37). In
1987, the first statin was approved for human use(38).
Statins are competitive inhibitors of the enzyme
HMGCoA reductase, the rate-limiting step in cholesterol
synthesis, which leads to an up-regulation of LDL recep-
tors in the liver. By 1994 evidence emerged that statins
not only decrease LDL-cholesterol but also reduce cardio-
vascular events(39). This has now been confirmed in
numerous studies, with a recent meta-analysis of
twenty-eight trials (including 186 854 participants) indicat-
ing that a 1 mM drop in LDL-cholesterol was associated
with a 21 % drop in major vascular events(40). Beneficial
effects were seen across all age groups and statin therapy
had no effect on non-vascular mortality, cancer death or
cancer incidence. Despite the apparent efficacy of statin
treatment, adherence to treatment has long been a prob-
lem due to perceived adverse effects. This was largely
fuelled by the removal of one form of the drug, cerivasta-
tin, from the market in 2001 due to fifty-two deaths
associated with rhabdomyolysis leading to kidney fail-
ure(41). In subsequent years, statin use has frequently
been claimed to be associated with a high incidence of
side-effects, including myopathy, new-onset diabetes mel-
litus and haemorrhagic stroke. Amid increasing concern
that such fears were limiting the potential benefit of statin
therapy, a recent review estimated that treatment of 10
000 patients for 5 years with an effective dose of statin
would only result in five cases of myopathy, 50–100
new cases of diabetes and 5–10 haemorrhagic strokes(42).
This was set against an estimated prevention of between
500 (primary prevention) and 1000 (secondary preven-
tion) vascular events. The authors concluded that most
of the cases of symptomatic adverse events (such as mus-
cle pain or weakness) were not actually caused by the
drug itself. It thus appears that unjustified concerns
about such side-effects are reducing adherence to statin
treatment and increasing risk of cardiovascular events.
In the UK, NICE recommend that statin therapy should
be considered for treatment of all subjects with a >10 %
risk of developing CVD in the next 10 years(43). Such
treatment should be in addition to continuing advice
relating to lifestyle risk factors including a reduction in
SFA intake to <7 % of total energy intake. It has been
suggested that this could potentially include 11·8 million
people in England including all males and females
between the ages of 75 and 84 years(44). Actually, statin
prescriptions increased dramatically between the years of
2000 and 2010 and now appear to be levelling off with
128 prescriptions per 1000 people in the UK in 2013(45).
New cholesterol-lowering therapies
Since the widespread introduction of statins for the treat-
ment of elevated plasma cholesterol, two further therapies
have emerged. In 2002, ezetimibe was shown to inhibit
cholesterol absorption from the intestine and, thereby
reduce plasma total LDL-cholesterol in human
subjects(46). It was subsequently shown to bind to
Niemann–Pick C1-like protein and thereby preventing
conformational changes that are necessary for the
translocation of cholesterol across the membrane into
the enterocyte(47). Ezetimibe is now prescribed as an
alternative treatment for those in whom statins are
contra-indicated, or as a complementary treatment in
patients (often suffering from heterozygous familial
hypercholesterolaemia) who fail to achieve adequate
reductions in plasma cholesterol on statins alone(43).
A recent meta-analysis of seven trials (including 31 048
patients) concluded that compared to statin treatment
alone, the addition of ezetimibe reduces the risk of myo-
cardial infarction and stroke, but without any effect on
all-cause and cardiovascular mortality(48).
The most recent treatment for elevated LDL-cholesterol
is the use of monoclonal antibodies raised against propro-
tein convertase subtilisin–kexin type 9 (PCSK-9). PCSK-9
is a protein that binds to LDL receptors in the liver and
prevents them from being recycled to the cell membrane,
thus reducing the rate of removal of LDL from the circu-
lation(49). The importance of PCSK-9 in regulating plasma
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LDL-cholesterol levels became evident in studies looking at
the impact of specific mutations in its genes. In individuals
in whom such mutations led to a ‘loss of function’ of the
protein, LDL-cholesterol was found to be significantly
reduced (15–28 %) and this was associated with a 47–88
% reduction in CHD(50). By contrast, other mutations lead-
ing to a ‘gain of function’ of PCSK-9 have been shown to
be associated with a hypercholesterolaemic phenotype and
a marked increase in cardiovascular risk(51). This led to the
development of PCSK-9 monoclonal antibodies for admin-
istration to patients to inhibit the activity of the protein.
Initial human trials demonstrated a robust lowering of
LDL-cholesterol by as much as 50–70 %(52). In a recent
double-blinded trial, one such antibody (evolcumab) was
given to a group of patients already being treated with
statins and resulted in a fall in LDL-cholesterol from
2·4 to 0·78 mM(53). This was associated with a significant
reduction in the primary clinical endpoint of the study
(cardiovascular death, myocardial infarction, stroke, hos-
pitalisation for unstable angina or coronary revascularisa-
tion). The high cost of such treatment (repeated injections
of antibodies) remains a major factor as to how such ther-
apies might be applied and, at present, NICE only recom-
mend their use in patients at high risk of CVD, with
primary hypercholesterolaemia (or mixed dyslipidaemia),
in whom LDL-cholesterol cannot be sufficiently lowered
with maximum lipid-lowering therapies(43). Table 2 com-
pares the outcome of some recent systematic reviews(54–56)
looking at the effects of statins alone or in combination
with ezetimibe or PCSK9 inhibitors.
Is diet important in patients treated with
cholesterol-lowering drugs?
As reviewed earlier, patients judged to be at high risk of
CVD (or who have suffered a CVD event), with elevated
LDL-cholesterol, are highly likely to be recommended to
undertake statin therapy. Should this prove to be ineffect-
ive, they may be offered combined therapy with ezetimibe
or even PCSK9 monoclonal antibodies. However, what-
ever drug regimen they are taking, they are also likely to
be advised to follow a diet low in SFA(43). This is based
on a supposition that the impact of such a diet is likely
to be, at least, additive in reducing LDL-cholesterol. As
previously described, statins act by inhibiting the action
of HMGCoA reductase, thereby reducing hepatic choles-
terol concentration and up-regulating LDL receptors.
Animal studies have clearly demonstrated that high SFA
diets reduce LDL receptor activity(57) which is associated
with a dose-dependent down-regulation of LDL receptor
gene expression(58). While the exact mechanism by which
SFA exert this effect has not been fully elucidated, it
appears to be through regulating the storage of cholesterol
ester within the cell and thereby modulating the amount of
free cholesterol available to regulate LDL receptor expres-
sion(59). Thus, conversely, if the amount of SFA in the diet
is reduced, then hepatic LDL receptor activity should
increase and more LDL particles should be removed
from the circulation. As statins and reduction in dietary
SFA are impacting on LDL receptor activity by independ-
ent mechanisms, it might appear logical to assume that
they will indeed be additive in their effects. However, in
human subjects, there is very little published evidence to
confirm this. An early study performed by Hunninghake
et al.(60) looked at the impact of Lovastatin on plasma
lipoproteins in patients who were either on a low- or high-fat
diet. The low-fat diet reduced LDL by 5 %, while Lovastatin
reduced it by 27 %. The combined effect was indeed found
to be additive. However, they also found that when patients
were on the low-fat diet, HDL-cholesterol was also signifi-
cantly lowered. As a result, there was no additional ben-
eficial change in the LDL:HDL ratio when drug-treated
patients undertook the low-fat diet. A similar result was
Table 1. Recent systematic reviews on the impact of dietary SFA on CVD
Authors Type of studies Conclusions and key findings
Jakobsen et al.(29) Cohort To reduce risk of CHD, SFA should be replaced with PUFA rather than MUFA or carbohydrate
Significant inverse association between PUFA intake and risk of coronary events (hazard ratio 0·87
(95 % CI 0·77, 0·97)
Skeaff and Miller(30) Cohort and
RCT
Probably no relationship between SFA and CHD. PUFA decreases risk
Relative risk of CHD event 0·84 (95 % CI 0·70, 1·00) per 5 % energy increase in PUFA
Mozaffarian et al.(31) RCT Consuming PUFA in place of SFA reduces CHD events
Relative risk of CHD event 0·90 (95 % CI 0·83, 0·97) per 5 % energy increase in PUFA
Siri-Tarino et al.(26) Cohort Insufficient evidence that SFA is associated with CHD or stroke
Relative risk between extreme quantiles of SFA intake for CVD events 1·00 (95 % CI 0·89, 1·11)
Chowdhury et al.(27) Cohort Evidence does not support the benefit of low SFA/high PUFA diet
Relative risks for coronary outcomes were 1·03 (95 % CI 0·98, 1·07) for SFA and 0·98 (0·90, 1·06)
for n-6 PUFA
Harcombe et al.(28) RCT Evidence of RCT before 1983 did not support the introduction of dietary guidelines
Relative risk for CHD death between intervention and control 0·989 (95 % CI 0·784, 1·247)
De Souza et al.(32) Cohort SFA not associated with any negative health outcomes but replacing SFA with PUFA reduced risk
of CHD
Relative risk of total CHD for SFA 1·04 (95 % CI 0·95, 1·17)
Hooper et al.(33) RCT Replacing SFA with PUFA significantly reduced the risk of CVD
Relative risk of reducing SFA on CVD 0·83 (95 % CI 0·72, 0·96)
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found when patients taking simvastatin who replaced diet-
ary SFA/TFA with a diet rich in MUFA and PUFA(61). In
fact, it is well established that SFA have the capacity to
increase HDL as well as LDL. Thus if LDL-cholesterol
is maximally reduced by drug therapy, then the main
impact of reducing SFA on lipoprotein metabolism may
be to reduce HDL-cholesterol which might be seen as det-
rimental. However, it should be remembered that diets rich
in SFA are often energy-dense, potentially leading to obes-
ity and insulin resistance, and associated with high red and
processed meat intake, all of which may be associated with
increased CVD risk.
It is also of interest to consider what dietary patterns
patients on long-term cholesterol-lowering drug therapy
are actually adopting. A review of data arising from
the National Health and Nutrition Examination Survey
in the USA revealed some interesting differences in
time trends in dietary behaviour between statin and non-
statin users(62). Within the period 2000–2001, statin users
consumed less dietary fat than non-users. However, in
the subsequent decade, while intake remained unchanged
in non-users, it actually increased in those taking the
drugs. As a result, over this period, the mean BMI
increased in those on statin, while it remained unaltered
in the control population. The authors concluded that
statin users may become less restrained in their dietary
choices. While this may not have major impacts on
plasma lipoproteins, again the potential impact on obes-
ity and associated morbidities should be considered.
Conclusions
There are widely varying patterns in the incidence of CVD
across the world, with marked decreases in early mortality
from such diseases in many high-income countries. This
appears to be due to a combination of improved outcome
following a cardiovascular event and reductions in risk fac-
tors, including LDL-cholesterol. The relative impact of
public health policies advocating a reduction in SFA intake
and the dramatic increase in availability of highly effective
cholesterol-lowering drugs remains to be fully established.
While at the present time, most patients at high risk of
developing CVD are prescribed statins, they continue to
be advised to follow a low SFA diet. While existing
evidence fails to confirm any major benefits of such a
dual regimen on plasma lipoprotein profile, the high energy
content of SFA-rich diets, often associated with high
intakes of red and processed meats, suggests it is prudent
to continue with such advice. Interactions between diet
and other lipid-lowering therapies (ezitimibe and PCSK9
monoclonal antibodies) remain largely unexplored.
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